R. Andrew Ramelmeier
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About R. Andrew Ramelmeier
Sangamo Therapeutics, Inc reported in an 8-K filed April 26, 2023 that R. Andrew Ramelmeier was terminated as Executive Vice President, Technical Operations, effective July 10, 2023. The proxy statement of Sangamo Therapeutics, Inc reports total compensation of $1,499,589 for R. Andrew Ramelmeier in fiscal 2022, including a base salary of $432,640. Disclosed compensation is on record for 4 fiscal years.
“In connection with Sangamo's restructuring and corresponding reduction in workforce, the employment of R. Andrew Ramelmeier, Ph.D., Executive Vice President, Technical Operations, will terminate effective as of July 10, 2023.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Sangamo Therapeutics, Inc (SGMOQ)
Proxy statement
Start not stated–2023-07-10
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Sangamo Therapeutics, Inc (SGMOQ) | Executive Vice President, Technical Operations | $432,640 | $1,499,589 |
| 2021 | Sangamo Therapeutics, Inc (SGMOQ) | Executive Vice President, Technical Operations | $416,000 | $1,690,594 |
| 2020 | Sangamo Therapeutics, Inc (SGMOQ) | Executive Vice President, Technical Operations | $416,000 | $1,534,700 |
| 2019 | Sangamo Therapeutics, Inc (SGMOQ) | Executive Vice President, Technical Operations | $382,965 | $1,104,540 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.